Molecular prediction of oseltamivir efficiency against probable influenza a (H1N1-2009) mutants: Molecular modeling approach

Amino Acids

Volumn 39, Issue 2, 2010, Pages 393-398

  Rungrotmongkol, Thanyada ^a   Malaisree, Maturos ^a   Nunthaboot, Nadtanet ^b   Sompornpisut, Pornthep ^a   Hannongbua, Supot ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

2009 H1N1 influenza a neuraminidase; Molecular dynamics simulations; Mutations; Oseltamivir resistance

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; HUMAN; HYDROGEN BOND; IC 50; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOLECULAR DYNAMICS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SIMULATION; VIRUS MUTATION; VIRUS STRAIN; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; COMPUTER SIMULATION; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; THERMODYNAMICS;

ANTIVIRAL AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; MODELS, MOLECULAR; MUTATION; OSELTAMIVIR; THERMODYNAMICS;

EID: 79951524535     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-009-0452-3     Document Type: Article

References (21)

1. Abed Y, Nehmé B, Baza M, Boivin G (2008) Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res 77:163-166
2. Åqvist J, Medina C, Samuelsson JE (1994) A new method for predicting binding affinity in computer-aided drug design. Protein Eng 7:385-391 (Pubitemid 24063137)
3. Boivin G, Goyette N (2002) Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 54:143-147
4. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Crowley M, Walker RC, Zhang W, Merz KM, Wang B, Hayik S, Roitberg A, Seabra G, Kolossváry I, Wong KF, Paesani F, Vanicek J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Mathews DH, Seetin MG, Sagui C, Babin V, Kollman PA (2008) AMBER10 University of California San Francisco
5. Chachra R, Rizzo RC (2008) Origins of resistance conferred by the R292K neuraminidase mutation via molecular dynamics and free energy calculations. J Chem Theory Comput 4:1526-1540
6. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258-1261
7. Ferraris O, Lina B (2008) Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 41:13-19
8. Hansson T, Marelius J, Åqvist JJ (1998) Ligand binding affinity prediction by linear interaction energy methods. J Comput Aided Mol Des 12:27-35
9. King G, Warshel A (1989) A surface constrained all-atom solvent model for effective simulations of polar solutions. J Chem Phys 91:3647-3661
10. Malaisree M, Rungrotmongkol T, Decha P, Intharathep P, Aruksakunwong O, Hannongbua S (2008) Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Proteins 71:1908-1918
11. Malaisree M, Rungrotmongkol T, Nunthaboot N, Aruksakunwong O, Intharathep P, Decha P, Sompornpisut P, Hannongbua S (2009) Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. Amino Acids 37:725-732
12. Marelius J, Kolmodin K, Feierberg I, Åqvist J (1998) Q: a molecular dynamics program for free energy calculations and empirical valence bond simulations in biomolecular systems. J Mol Graph Model 16:213-225 (Pubitemid 30069589)
13. Mishin VP, Hayden FG, Gubareva LV (2005) Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49:4515-4520
14. Rungrotmongkol T, Intharathep P, Malaisree M, Nunthaboot N, Kaiyawet N, Sompornpisut P, Payungporn S, Poovorawan Y, Hannongbua S (2009a) Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem Biophys Res Commun 385:390-394
15. Rungrotmongkol T, Udommaneethanakit T, Malaisree M, Nunthaboot N, Intharathep P, Sompornpisut P, Hannongbua S (2009b) How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? Biophys Chem 145:29-36
16. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:327-341
17. Wall ID, Leach AR, Salt DW, Ford MG, Essex JW (1999) Binding constants of neuraminidase inhibitors: an investigation of the linear interaction energy method. J Med Chem 42:5142-5152
18. Wang NX, Zheng JJ (2009) Computational studies of H5N1 influenza virus resistance to oseltamivir. Protein Sci 18:707-715
19. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA (2005) Neuraminidase inhibitor resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 49:4075-4084
20. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA (2007) Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 81:12418-12426
21. Zürcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL (2006) Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 58:723-732